Last week, President Donald Trump announced a deal with pharmaceutical company Merck KGaA and its U.S. subsidiary, EMD Serono, to sharply reduce the cost of some fertility drugs used for in-vitro fertilization, in exchange for a three-year reprieve on some of the tariffs levied on pharmaceutical imports (The Cancer Letter, Oct. 24, 2025).
President Donald Trump has announced a deal with pharmaceutical company Merck KGaA and its U.S. subsidiary, EMD Serono, to sharply reduce the cost of certain fertility drugs used for in-vitro fertilization, or IVF.
